Jpmorgan Chase & CO Adicet Bio, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ACET
# of Institutions
92Shares Held
66.3MCall Options Held
4.3KPut Options Held
36.3K-
Orbimed Advisors LLC San Diego, CA11.4MShares$14.4 Million0.33% of portfolio
-
Tang Capital Management LLC San Diego, CA8.22MShares$10.4 Million1.21% of portfolio
-
Ra Capital Management, L.P. Boston, MA7.54MShares$9.5 Million0.14% of portfolio
-
Goldman Sachs Group Inc New York, NY4.28MShares$5.4 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.62MShares$4.56 Million0.0% of portfolio
About Adicet Bio, Inc.
- Ticker ACET
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,030,800
- Market Cap $50.4M
- Description
- Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...